文献速递骨软组织肉瘤与黑色素瘤

真实世界数据:抗PD-1联合仑伐替尼用于经治晚期黑色素瘤的DeCOG回顾性研究

Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study.
PubMed 文献 · Eur J Cancer · 2026-02-20

该多中心回顾性DeCOG研究纳入120例经抗PD-1治疗失败后的晚期黑色素瘤患者,评估抗PD-1联合仑伐替尼的疗效与安全性。结果显示客观缓解率23%,中位无进展生存期4个月,中位总生存期10个月,≥3级治疗相关不良事件发生率21%,提示该方案在重度经治患者中具有一定疗效。

要点

  • 客观缓解率23%,中位缓解持续时间10个月,疾病控制率47%
  • 中位无进展生存期4个月,中位总生存期10个月,12个月PFS率17%、OS率42%
  • ≥3级治疗相关不良事件发生率21%,安全性总体可控

核心结论

  • 在真实世界重度经治晚期黑色素瘤患者中,抗PD-1联合仑伐替尼显示出有意义的疗效,主要体现在BRAF野生型患者亚组。

研究设计与样本

  • 德国与瑞士11家主要皮肤肿瘤中心开展的多中心回顾性DeCOG研究,纳入2020年10月至2025年3月间抗PD-1治疗失败后接受抗PD-1联合仑伐替尼的晚期黑色素瘤患者120例。

主要发现

  • 120例患者中位年龄59岁,70%为男性,38%的ECOG体能状态评分大于1。
  • 69%的患者有至少3个转移部位,42%存在脑转移,58%乳酸脱氢酶升高。
  • 中位随访13.4个月,患者既往接受中位2线全身治疗,98%曾接受伊匹木单抗联合纳武利尤单抗治疗,66%对既往免疫检查点抑制剂原发耐药。
  • 客观缓解率为23%,中位缓解持续时间10个月,疾病控制率47%。
  • 中位无进展生存期4个月,中位总生存期10个月,12个月无进展生存率和总生存率分别为17%和42%,23%的患者获得超过6个月的持久疾病控制且其中位无进展生存期达21个月。

关键数值与推荐

  • 客观缓解率23%,疾病控制率47%,中位缓解持续时间10个月。
  • 中位无进展生存期4个月,中位总生存期10个月。
  • 12个月无进展生存率17%,12个月总生存率42%。
  • ≥3级治疗相关不良事件发生率为21%。

临床怎么用

  • 对于既往抗PD-1治疗失败且缺乏其他获批治疗选择的晚期黑色素瘤患者,抗PD-1联合仑伐替尼可作为一种治疗选择,尤其可能使BRAF野生型患者获益。

局限性

  • 本研究为回顾性设计,缺乏随机对照,可能存在选择偏倚和信息偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with advanced melanoma progressing after immune checkpoint inhibition (ICI) and BRAF/MEK inhibition have limited therapeutic options. In the LEAP-004 trial, pembrolizumab plus lenvatinib demonstrated activity in PD-1-refractory melanoma. The combination has emerged as a potential option when approved therapies have been exhausted; however, real-world evidence regarding its efficacy remains limited. METHODS: This retrospective, multicenter DeCOG study included patients with advanced melanoma treated with anti-PD-1 plus lenvatinib after failure of anti-PD-1-based therapy at 11 major skin-cancer centers in Germany and Switzerland between October 2020 and March 2025. RESULTS: Overall, 120 patients were analyzed (median age 59 years); 70 % were male and 38 % had an ECOG performance status > 1. Most patients had ≥ 3 metastatic sites (69 %), brain metastases (42 %), and elevated LDH (58 %). Median follow-up was 13.4 months. Patients received a median of two prior systemic therapy lines; 98 % had been pretreated with ipilimumab/nivolumab, and 66 % exhibited primary resistance to prior ICI. The objective response rate was 23 %, with a median duration of response of 10 months; disease control rate was 47 %. Median progression-free survival (mPFS) was 4 months and median overall survival (mOS) was 10 months, with 12-month PFS and OS rates of 17 % and 42 %, respectively. Durable disease control beyond six months was observed in 23 % of patients, with mPFS of 21 months. Grade ≥ 3 treatment-related adverse events occurred in 21 % of patients. CONCLUSIONS: In this real-world cohort, anti-PD-1 plus lenvatinib demonstrated meaningful efficacy in a subset of heavily pretreated patients, predominantly in those with BRAF wild-type melanoma.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Albrecht LJ, Garnier J, Zaremba A, et al. Real-world data on anti-PD-1 plus lenvatinib as a treatment option in pretreated advanced melanoma patients - a retrospective DeCOG study. Eur J Cancer. 2026. PMID: 41747312. doi:10.1016/j.ejca.2026.116595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。